Introduction {#s1}
============

Sporadic colorectal cancer (CRC) is considered to be a multifactorial disease, in which multiple exposures to endogenous factors and dietary carcinogens interact with individual genetic background in a complex manner resulting in modulation of the risk [@pone.0100487-Ishibe1]. In 2010, an estimated 142,570 new cases will be diagnosed and 51,370 deaths will occur in the whole world [@pone.0100487-Jemal1]. Epidemiologic studies on Western populations have emphasized the large contribution of food and lifestyle to sporadic CRC risk [@pone.0100487-GerhardssondeVerdier1]--[@pone.0100487-Kushi1]. High-fat and low-fiber diets, as well as alcohol, tobacco, and red or processed meat consumption, have been shown to produce high levels of polycyclic aromatic hydrocarbons and heterocyclic aromatic amines. These procarcinogenic agents are potentially very harmful and may play a key role in the malignant transformation of cells by interacting with DNA [@pone.0100487-Potter1]. It has been proposed that this risk may be due to carcinogenic polycyclic aromatic hydrocarbons (PAHs) and heterocyclic amines produced when meat is cooked at high temperatures [@pone.0100487-Norat1].

CYP1B1 gene is located on chr2p22-p21, which is involved in the metabolic activation of polycyclic aromatic hydrocarbons (PAHs) including benzo(a)pyrene and dimethylbenz(a)anthracene (DMBA), but with a product distribution that is distinct from CYP1A1 [@pone.0100487-Buters1], [@pone.0100487-Shimada1]. Several lines of evidence suggest that CYP1B1 plays a role in carcinogenesis. CYP1B1 is commonly over-expressed inhumanmalignancies [@pone.0100487-Murray1] and activates a variety of carcinogens. For example, CYP1B1 catalyzes both the formation of dihydrodiols of specific PAHs and their subsequent oxidation to carcinogenic dihydrodiol epoxides [@pone.0100487-Kim1]. In humans, CYP1B1 is genetically polymorphic and more than 50 single nucleotide polymorphisms (SNPs) have been reported so far, of which certain deleterious mutations are associated with primary congenital glaucoma [@pone.0100487-Stoilov1]. Of the most common SNPs of CYP1B1 gene, four have been reported to result in amino acid substitutions including Arg by Gly at codon 48 (rs10012), Leu by Val at codon 432 (rs1056836) and Asn by Ser at codon 453 (rs1800440). CYP 1A2 is an important gene in catalyzing 2- and 4-hydroxylations of estrogens [@pone.0100487-Yamazaki1]--[@pone.0100487-Tsuchiya1] and metabolism of carcinogens [@pone.0100487-Nebert2]--[@pone.0100487-Eaton1]. CYP1A2\*1C, located in the 5′-non-coding promoter region of CYP1A2, was reported to be associated with decreased enzyme inducibility in Japanese smokers but seems to be very rare [@pone.0100487-Nakajima1].

To date, a number of molecular epidemiological studies have been done to evaluate the association between CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and colorectal cancer risk in diverse populations [@pone.0100487-Wang1]--[@pone.0100487-Sainz2], [@pone.0100487-Hlavata1], [@pone.0100487-Trubicka1], [@pone.0100487-Cotterchio1]--[@pone.0100487-Wang2]. However, the results were inconsistent or even contradictory. Therefore, we performed a comprehensive meta-analysis by including the most recent and relevant articles to identify statistical evidence of the association between CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and risk of colorectal cancer that have been investigated. Meta-analysis is a powerful tool for summarizing the different studies. It can not only overcome the problem of small size and inadequate statistical power of genetic studies of complex traits, but also provide more reliable results than a single case--control study.

Materials and Methods {#s2}
=====================

Identification and eligibility of relevant studies {#s2a}
--------------------------------------------------

A comprehensive literature search was performed using the PubMed, CNKI, and Medline database for relevant articles published (the last search update was Sep 10, 2013) with the following key words "CYP1A2", "CYP1B1", "polymorphism", "Variant", or "Mutation", and "Colorectal". In addition, studies were identified by a manual search of the reference lists of reviews and retrieved studies. We included all the case--control studies and cohort studies that investigated the association between CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and colorectal cancer risk with genotyping data. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications.

Inclusion criteria {#s2b}
------------------

The included studies have to meet the following criteria: (1) only the case--control studies or cohort studies were considered; (2) evaluated the CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and the risk of colorectal cancer; (3) the genotype distribution of the polymorphism in cases and controls were described in details and the results were expressed as odds ratio (OR) and corresponding 95% confidence interval (95% CI). Major reasons for exclusion of studies were as follows: (1) not for cancer research; (2) only case population; (3) duplicate of previous publication (When the same patient population was used in several publications, only the most recent, largest or complete study was included following careful examination).

Data extraction {#s2c}
---------------

Information was carefully extracted from all eligible studies independently by two investigators according to the inclusion criteria listed above. The following data were collected from each study: first author\'s name, year of publication, country of origin, ethnicity, source of controls (population-based controls, hospital-based controls, and family-based controls), and numbers of cases and controls in the CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly genotypes whenever possible. Ethnicity was categorized as "Caucasian" and "Asian". When one study did not state which ethnic groups was included or if it was impossible to separate participants according to phenotype, the sample was termed as "mixed population". We did not define any minimum number of patients to include in this meta-analysis. Articles that reported different ethnic groups and different countries or locations, we considered them different study samples for each category cited above.

Statistical analysis {#s2d}
--------------------

Crude odds ratios (ORs) together with their corresponding 95% confidence intervals (95% CIs) were used to assess the strength of association between the CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and colorectal cancer risk. The pooled ORs were performed for dominant model (CYP1A2\*F: CY + YY vs. CC; CYP1B1 Leu432Val: Leu/Val + Val/Val vs. Leu/Leu; CYP1B1 Asn453Ser: Asn/Ser + Ser/Ser vs. Asn/Asn; CYP1B1 Arg48Gly: Arg/Gly + Gly/Gly vs. Arg/Arg), recessive model (CYP1A2\*F: YY vs. CC + CY; CYP1B1 Leu432Val: Val/Val vs. Leu/Leu + Leu/Val; CYP1B1 Asn453Ser: Ser/Ser vs. Asn/Asn + Asn/Ser; CYP1B1 Arg48Gly: Gly/Gly vs. Arg/Arg + Arg/Gly), co-dominant model (CYP1A2\*F: YY vs. CC and CY vs. CC; CYP1B1 Leu432Val: Val/Val vs. Leu/Leu and Leu/Val vs. Leu/Leu; CYP1B1 Asn453Ser: Ser/Ser vs. Asn/Asn and Asn/Ser vs. Asn/Asn; CYP1B1 Arg48Gly: Gly/Gly vs. Arg/Arg and Arg/Gly vs. Arg/Arg), and additive model (CYP1A2\*F: Y vs. C; CYP1B1 Asn453Ser: Ser/Asn; CYP1B1 Asn453Ser: Ser vs. Asn; CYP1B1 Arg48Gly: Gly vs. Arg), respectively. Between-study heterogeneity was assessed by calculating *Q*-statistic (Heterogeneity was considered statistically significant if *P*\<0.10) [@pone.0100487-Davey1] and quantified using the *I* ^2^ value, Venice criteria [@pone.0100487-Ioannidis1] for the *I* ^2^ test included: "*I* ^2^\<25% represents no heterogeneity, *I* ^2^ = 25--50% represents moderate heterogeneity, *I* ^2^ = 50--75% represents large heterogeneity, and *I* ^2^\>75% represents extreme heterogeneity". If results were not heterogeneous, the pooled ORs were calculated by the fixed-effect model (we used the *Q*-statistic, which represents the magnitude of heterogeneity between-studies) [@pone.0100487-Mantel1]. Otherwise, a random effect model was used (when the heterogeneity between-studies were significant) [@pone.0100487-DerSimonian1]. We also performed subgroup analysis by ethnicity and source of controls were conducted. Moreover, sensitivity analysis was performed by excluding a single study each time. We also ranked studies according to sample size, and then repeated this meta-analysis. Sample size was classified according to a minimum of 200 participants and those with fewer than 200 participants. The cite criteria were previously described [@pone.0100487-Klug1]. HWE was calculated by using the goodness-of-fit test, and deviation was considered when *P*\<0.05. Begg\'s funnel plots [@pone.0100487-Begg1] and Egger\'s linear regression test [@pone.0100487-Egger1] were used to assess publication bias. We opted for using ethnicity, source of controls, menopausal status, and sample size as possible different sources of heterogeneity. All of the calculations were performed using STATA version 10.0 (STATA Corporation, College Station, TX).

Results {#s3}
=======

Literature search and meta-analysis databases {#s3a}
---------------------------------------------

Relevant publications were retrieved and preliminarily screened. As shown in [**Fig. 1**](#pone-0100487-g001){ref-type="fig"}, 43 publications were identified, among which 6 irrelevant papers were excluded. Thus, 37 publications were eligible. Among these publications, 14 articles were excluded because they were review articles, case reports, and other polymorphisms of CYP1A2 and CYP1B1. As summarized in [**Table 1**](#pone-0100487-t001){ref-type="table"}, 23 articles with 39 studies were selected in this meta-analysis, including 5,817 cases and 6,544 controls for CYP1A2\*F (from 13 studies), 9,219 cases and 10,406 controls for CYP1B1 Leu432Val (from 12 studies), 6,840 cases and 7,761 controls for CYP1B1 Asn453Ser (from 8 studies), and 4,302 cases and 4,791 controls for CYP1B1 Arg48Gly (from 6 studies). Among these studies, eight were Caucasians, four were Asians, and 1 mixed populations for CYP1A2\*F. All studies were Caucasians except for one study was mixed population for CYP1B1 polymorphisms. The distribution of genotypes in the controls was consistent with Hardy--Weinberg equilibrium in all studies. All of the cases were pathologically confirmed.

![Study flow chart explaining the selection of the 23 eligible articles included in the meta-analysis.](pone.0100487.g001){#pone-0100487-g001}
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###### Main characteristics of all studies included in the meta-analysis.

![](pone.0100487.t001){#pone-0100487-t001-1}

  First author/Year                            Country   Ethnicity   SC   Genotype distribution   HWE   No. of case/control                        
  ------------------------------------------- --------- ----------- ---- ----------------------- ----- --------------------- ----- ----- ----- --- -----------
  CYP1A2\*F                                                                                                                                        
  Wang [@pone.0100487-Wang1] 2012                USA       Mixed     FB            164            117           24            184   144   29    Y    305/357
  Rudolph [@pone.0100487-Rudolph1] 2011        German    Caucasian   PB            354            261           63            353   280   47    Y    678/680
  Sainz [@pone.0100487-Sainz1] 2011            German    Caucasian   PB            872            735           157           887   732   167   Y   1764/1786
  Cleary [@pone.0100487-Cleary1] 2010          Canada    Caucasian   PB            598            461           106           648   517   125   Y   1165/1290
  Kobayashi [@pone.0100487-Kobayashi1] 2009     Japan      Asian     HB            53             40            11            96    94    35    Y    104/225
  Saebø [@pone.0100487-Saeb1] 2008             Norway    Caucasian   HB            97             87            14            122   84    16    Y    198/222
  Sachse [@pone.0100487-Sachse1] 2002            UK      Caucasian   PB            264            193           33            325   233   35    Y    490/593
  Yoshida [@pone.0100487-Yoshida1] 2007         Japan      Asian     HB            26             32             6            42    52    17    Y    64/111
  Kiss [@pone.0100487-Kiss1] 2007              Hungary   Caucasian   HB            219            212           69            228   207   65    Y    500/500
  Küry [@pone.0100487-Kry1] 2007               France    Caucasian   HB            514            420           79            553   480   85    Y   1013/1118
  Bae [@pone.0100487-Bae1] 2006                 Korea      Asian     HB            24             71            16            44    37    12    Y    111/93
  Chen [@pone.0100487-Chen1] 2005               China      Asian     PB            19             62            57            47    133   160   Y    138/340
  Landi [@pone.0100487-Landi1] 2005             Spain    Caucasian   HB            141            172           48            158   137   26    Y    361/321
  CYP1B1 Leu432Val (rs1056836)                                                                                                                     

  First author/Year                                      Country    Ethnicity   SC   Genotype distribution   HWE    No. of case/control                         
  ---------------------------------------------------- ----------- ----------- ---- ----------------------- ------ --------------------- ----- ------ ----- --- -----------
  Wang [@pone.0100487-Wang2] 2012                          USA        Mixed     FB            86             139            75            118   151    81    Y    300/350
  Rudolph et al. [@pone.0100487-Rudolph2] 2011           German     Caucasian   PB            220            320            128           224   339    106   Y    668/669
  Sainz et al. [@pone.0100487-Sainz2] 2011               German     Caucasian   PB            237            339            143           245   358    110   Y    719/713
  Cleary et al. [@pone.0100487-Cleary1] 2010             Canada     Caucasian   PB            391            547            224           424   617    250   Y   1162/1291
  Hlavata et al. [@pone.0100487-Hlavata1] 2010            Czech     Caucasian   HB            174            237            84            155   262    78    Y    495/495
  Trubicka et al. [@pone.0100487-Trubicka1] 2010         Poland     Caucasian   PB            214            275            108           206   265    127   Y    597/598
  Sachse et al. [@pone.0100487-Sachse1] 2002               UK       Caucasian   PB            141            258            91            187   283    123   Y    490/593
  Cotterchio et al. [@pone.0100487-Cotterchio1] 2008     Canada     Caucasian   PB            283            382            166           407   604    237   Y   831/1248
  Küry et al. [@pone.0100487-Kry2] 2007                  France     Caucasian   PB            317            507            189           368   576    174   Y   1013/1118
  Bethke et al. [@pone.0100487-Bethke1] 2007               UK       Caucasian   HB            519            1277           763           538   1365   792   Y   2559/2695
  Huber [@pone.0100487-Huber1] 2005                     Australia   Caucasian   HB            14              28                          112   225          Y    42/337
  Landi [@pone.0100487-Landi2] 2005                       Spain     Caucasian   HB            128            151            64            101   139    59    Y    343/299
  Asn453Ser (rs1800440)                                                                                                                                         

  First author/Year                               Country    Ethnicity   SC   Genotype distribution   HWE   No. of case/control                         
  --------------------------------------------- ----------- ----------- ---- ----------------------- ----- --------------------- ------- ----- ---- --- -----------
  Rudolph [@pone.0100487-Rudolph2] 2011           German     Caucasian   PB            467            187           22             452    202   26   Y    676/680
  Sainz [@pone.0100487-Sainz2] 2011               German     Caucasian   PB            505            203           23             473    222   27   Y    731/722
  Cleary [@pone.0100487-Cleary1] 2010             Canada     Caucasian   PB            775            354           34             897    349   46   Y   1163/1292
  Hlavata [@pone.0100487-Hlavata1] 2010            Czech     Caucasian   HB            353            134            8             320    163   12   Y    495/495
  Cotterchio [@pone.0100487-Cotterchio1] 2008     Canada     Caucasian   PB            549            262           21             867    340   42   Y   832/1249
  Bethke [@pone.0100487-Bethke1] 2007               UK       Caucasian   HB           1734            739           86            1,790   828   76   Y   2559/2694
  Huber [@pone.0100487-Huber1] 2005              Australia   Caucasian   HB            26             16                           219    113        Y    42/332
  Landi [@pone.0100487-Landi2] 2005                Spain     Caucasian   HB            219            107           16             190    90    17   Y    342/297
  Arg48Gly (rs10012)                                                                                                                                    

  First author/Year                              Country   Ethnicity   SC   Genotype distribution   HWE   No. of case/control                        
  --------------------------------------------- --------- ----------- ---- ----------------------- ----- --------------------- ----- ----- ----- --- -----------
  Rudolph [@pone.0100487-Rudolph2] 2011          German    Caucasian   PB            329            295           55            322   299   54    Y    679/675
  Sainz [@pone.0100487-Sainz2] 2011              German    Caucasian   PB            354            318           60            342   321   57    Y    732/720
  Cleary [@pone.0100487-Cleary1] 2010            Canada    Caucasian   PB            593            478           92            651   529   112   Y   1163/1292
  Trubicka [@pone.0100487-Trubicka1] 2010        Poland    Caucasian   PB            261            266           70            265   265   67    Y    597/597
  Cotterchio [@pone.0100487-Cotterchio1] 2008    Canada    Caucasian   PB            424            347           61            624   518   107   Y   832/1249
  Landi [@pone.0100487-Landi2] 2005               Spain    Caucasian   HB            169            101           29            161   87    10    Y    299/258

PB population-based studies, HB hospital-based studies, FB family-based studies, Y yes, N no, SC source of control, HWE Hardy--Weinberg equilibrium.

Meta-analysis results {#s3b}
---------------------

[**Table 2**](#pone-0100487-t002){ref-type="table"} lists the main results of the meta-analysis of CYP1A2\*F polymorphism and colorectal cancer risk. Overall, no significant association was found between CYP1A2\*F polymorphism and colorectal cancer risk (dominant model: OR = 1.05, 95% CI = 0.94--1.18, *P* ~h~ = 0.010, *I* ^2^ = 54.1%; recessive model: OR = 1.01, 95% CI = 0.90--1.13, *P* ~h~ = 0.426, *I* ^2^ = 2.0%; homozygote model: OR = 1.04, 95% CI = 0.93--1.17, *P* ~h~ = 0.144, *I* ^2^ = 30.0%; heterozygote model: OR = 1.05, 95% CI = 0.94--1.17, *P* ~h~ = 0.023, *I* ^2^ = 49.2%; additive model: OR = 1.03, 95% CI = 0.95--1.11, *P* ~h~ = 0.026, *I* ^2^ = 48.2%, [**Fig. 2**](#pone-0100487-g002){ref-type="fig"}). Significant between-study heterogeneity was detected. Hence, we performed the stratified analyses according to ethnicity and source of controls. In the stratified analysis by ethnicity, no significant association was found among Caucasians (dominant model: OR = 1.02, 95% CI = 0.95--1.10, *P* ~h~ = 0.233, *I* ^2^ = 24.6%; recessive model: OR = 1.06, 95% CI = 0.94--1.20, *P* ~h~ = 0.387, *I* ^2^ = 5.6%; homozygote model: OR = 1.07, 95% CI = 0.94--1.21, *P* ~h~ = 0.224, *I* ^2^ = 25.6%; heterozygote model: OR = 1.01, 95% CI = 0.94--1.09, *P* ~h~ = 0.403, *I* ^2^ = 3.5%; additive model: OR = 1.03, 95% CI = 0.97--1.08, *P* ~h~ = 0.157, *I* ^2^ = 34.0%, [**Fig. 3**](#pone-0100487-g003){ref-type="fig"}) and Asians (recessive model: OR = 0.78, 95% CI = 0.57--1.05, *P* ~h~ = 0.681, *I* ^2^ = 0.0%; homozygote model: OR = 0.91, 95% CI = 0.49--1.68, *P* ~h~ = 0.076, *I* ^2^ = 56.5%; additive model: OR = 0.98, 95% CI = 0.69--1.42, *P* ~h~ = 0.009, *I* ^2^ = 74.3%, [**Fig. 4**](#pone-0100487-g004){ref-type="fig"}). In addition, high heterogeneity was found among Asians (dominant model: *I* ^2^ = 81.3%; heterozygote model: *I* ^2^ = 79.0). When grouped by source of control, there was still no evidence of significant association.

![Forest plot of CYP1A2\*F polymorphism and colorectal cancer risk among overall analysis (additive model).](pone.0100487.g002){#pone-0100487-g002}

![Forest plot of CYP1A2\*F polymorphism and colorectal cancer risk among Caucasians (additive model).](pone.0100487.g003){#pone-0100487-g003}

![Forest plot of CYP1A2\*F polymorphism and colorectal cancer risk among Asians (additive model).](pone.0100487.g004){#pone-0100487-g004}
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###### Results of meta-analysis for CYP1A2 and CYP1B1 polymorphisms on colorectal cancer risk.[1](#nt102){ref-type="table-fn"}

![](pone.0100487.t002){#pone-0100487-t002-2}

  Generic model         Recessive model    Dominant model     Homozygote   Heterozygote            Additive model                                                                                                                                               
  -------------------- ----------------- ------------------- ------------ -------------- ---------------------------------- ------- ------ --------------------- ------- ------ ---------------------------------- ------- ------ --------------------- ------- ------
  Overall               13 (6891/7636)    1.01 (0.90--1.13)     0.426          2.0              1.05 (0.94--1.18)\*          0.010   54.1    1.09 (0.93--1.17)    0.144   30.0         1.05 (0.94--1.17)\*          0.023   49.2   1.03 (0.95--1.11)\*   0.026   48.2
  Ethnicity                                                                                                                                                                                                                                                     
  Caucasian              8 (6169/6510)    1.06 (0.94--1.20)     0.387          5.6               1.02 (0.95--1.10)           0.233   24.6    1.07 (0.94--1.21)    0.224   25.6          1.01 (0.94--1.09)           0.403   3.5     1.03 (0.97--1.08)    0.157   34.0
  Asian                   4 (417/769)     0.78 (0.57--1.05)     0.681          0.0        [2](#nt103){ref-type="table-fn"}   0.001   81.3   0.91 (0.49--1.68)\*   0.076   56.5   [2](#nt103){ref-type="table-fn"}   0.003   79.0   0.98 (0.69--1.42)\*   0.009   74.3
  Source of controls                                                                                                                                                                                                                                            
  PB                     5 (4235/4689)    0.98 (0.85--1.13)     0.329          13.3              0.99 (0.91--1.08)           0.982   0.0     1.00 (0.86--1.17)    0.566   0.0           0.99 (0.91--1.09)           0.929   0.0     0.99 (0.93--1.06)    0.795   0.0
  HB                     7 (2351/2590)    1.06 (0.88--1.28)     0.303          16.6             1.18 (0.91--1.53)\*          0.001   74.5   1.14 (0.82--1.59)\*   0.040   54.5         1.20 (0.93--1.55)\*          0.002   71.1   1.09 (0.92--1.30)\*   0.004   69.1

  Leu432Val    N (case/control)    Recessive model    Dominant model   Homozygote     Heterozygote      Additive model                                                                                                        
  ----------- ------------------ ------------------- ---------------- ------------ ------------------- ---------------- ----- ------------------- ------- ----- ------------------- ------- ----- ------------------- ------- -----
  Overall      12 (9219/10406)    1.05 (0.98--1.13)       0.251           20.3      1.00 (0.94--1.06)       0.770        0.0   1.04 (0.96--1.13)   0.383   6.3   0.98 (0.91--1.04)   0.687   0.0   1.02 (0.98--1.06)   0.498   0.0

  Asn453Ser             N (case/control)    Recessive model    Dominant model   Homozygote      Heterozygote       Additive model                                                                                                             
  -------------------- ------------------ ------------------- ---------------- ------------ --------------------- ---------------- ------ ------------------- ------- ------ --------------------- ------- ------ ------------------- ------- ------
  Overall                8 (6840/7761)     0.92 (0.76--1.11)       0.617           0.0       0.97 (0.87--1.08)\*       0.053        49.6   0.92 (0.76--1.11)   0.685   0.0    0.97 (0.86--1.11)\*   0.016   61.8   0.97 (0.91--1.03)   0.135   38.6
  Source of controls                                                                                                                                                                                                                          
  PB                     4 (3402/3943)     0.81 (0.62--1.05)       0.988           0.0       1.01 (0.86--1.19)\*       0.054        60.8   0.82 (0.63--1.07)   0.996   0.0     0.90 (0.81--1.01)    0.275   22.5   0.94 (0.86--1.03)   0.183   41.1
  HB                     4 (3438/3818)     1.07 (0.81--1.40)       0.332           9.2        0.92 (0.83--1.02)        0.300        18.1   1.04 (0.79--1.37)   0.310   14.6   1.04 (0.87--1.23)\*   0.036   64.9   1.00 (0.92--1.09)   0.143   44.8

  Arg48Gly    N (case/control)    Recessive model    Dominant model   Homozygote     Heterozygote      Additive model                                                                                                         
  ---------- ------------------ ------------------- ---------------- ------------ ------------------- ---------------- ----- ------------------- ------- ------ ------------------- ------- ----- ------------------- ------- ------
  Overall      6 (4302/4791)     1.00 (0.86--1.16)       0.138           40.1      0.99 (0.91--1.08)       0.780        0.0   1.00 (0.86--1.16)   0.124   42.1   0.99 (0.91--1.08)   0.989   0.0   1.00 (0.93--1.06)   0.286   19.6

All summary ORs were calculated using fixed-effects models. In the case of significant heterogeneity (indicated by \*), ORs were calculated using random-effects models.

The results were excluded due to high heterogeneity.

[**Table 2**](#pone-0100487-t002){ref-type="table"} also lists the main results of the meta-analysis of CYP1B1 Leu432Val polymorphism and colorectal cancer risk. Overall, no significant association was found between CYP1B1 Leu432Val polymorphism and colorectal cancer susceptibility (dominant model: OR = 1.00, 95% CI = 0.94--1.06, *P* ~h~ = 0.770, *I* ^2^ = 0.0%; recessive model: OR = 1.05, 95% CI = 0.98--1.13, *P* ~h~ = 0.251, *I* ^2^ = 20.3%; homozygote model: OR = 1.04, 95% CI = 0.96--1.13, *P* ~h~ = 0.383, *I* ^2^ = 6.3%; heterozygote model: OR = 0.98, 95% CI = 0.91--1.04, *P* ~h~ = 0.687, *I* ^2^ = 0.0%; additive model: OR = 1.02, 95% CI = 0.98--1.06, *P* ~h~ = 0.498, *I* ^2^ = 0.0%).

[**Table 2**](#pone-0100487-t002){ref-type="table"} also lists the main results of the meta-analysis of CYP1B1 Asn453Ser polymorphism and colorectal cancer risk. Overall, no significant association was found between CYP1B1 Asn453Ser polymorphism and colorectal cancer susceptibility (dominant model: OR = 0.97, 95% CI = 0.87--1.08, *P* ~h~ = 0.053, *I* ^2^ = 49.6%; recessive model: OR = 0.92, 95% CI = 0.76--1.11, *P* ~h~ = 0.617, *I* ^2^ = 0.0%; homozygote model: OR = 0.92, 95% CI = 0.76--1.11, *P* ~h~ = 0.685, *I* ^2^ = 0.0%; heterozygote model: OR = 0.97, 95% CI = 0.86--1.11, *P* ~h~ = 0.016, *I* ^2^ = 61.8%; additive model: OR = 0.97, 95% CI = 0.91--1.03, *P* ~h~ = 0.135, *I* ^2^ = 38.6%). Significant between-study heterogeneity was detected. Hence, we performed the stratified analysis according to source of controls. And in the subgroup analysis by source of controls, there was still no significant association detected in any genetic model.

[**Table 2**](#pone-0100487-t002){ref-type="table"} also lists the main results of the meta-analysis of CYP1B1 Arg48Gly polymorphism and colorectal cancer risk. Overall, no significant association was found between CYP1B1 Arg48Gly polymorphism and colorectal cancer susceptibility (dominant model: OR = 0.99, 95% CI = 0.91--1.08, *P* ~h~ = 0.780, *I* ^2^ = 0.0%; recessive model: OR = 1.00, 95% CI = 0.86--1.16, *P* ~h~ = 0.138, *I* ^2^ = 40.1%; homozygote model: OR = 1.00, 95% CI = 0.86--1.16, *P* ~h~ = 0.124, *I* ^2^ = 42.1%; heterozygote model: OR = 0.99, 95% CI = 0.91--1.08, *P* ~h~ = 0.989, *I* ^2^ = 0.0%; additive model: OR = 0.97, 95% CI = 0.91--1.03, *P* ~h~ = 0.135, *I* ^2^ = 38.6%).

Test of heterogeneity and sensitivity {#s3c}
-------------------------------------

There was significant heterogeneity among these studies for dominant model comparison (*P* ~h~ = 0.008 for CYP1A2\*F and *P* ~h~ = 0.053 for CYP1B1 Asn453Ser), heterozygote model comparison (*P* ~h~ = 0.020 for CYP1A2\*F and *P* ~h~ = 0.016 for CYP1B1 Asn453Ser) and additive model comparison (*P* ~h~ = 0.022 for CYP1A2\*F). Then, we assessed the source of heterogeneity by ethnicity and source of controls. We found that ethnicity and source of controls (*data not shown*) did not contribute to substantial heterogeneity. Sensitivity analysis was conducted to determine whether modification of the inclusion criteria of this meta-analysis affected the results. Although the sample size for cases and controls in all eligible studies ranged from 175 to 2,455, the corresponding pooled ORs were not qualitatively altered with or without the study of small sample. In addition, a single study involved in the meta--analysis was deleted each time to reflect the influence of individual data set to the pooled ORs. The results were also not qualitatively altered.

Publication bias {#s3d}
----------------

Both Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias of literatures. The Egger\'s test results and Begg\'s funnel plot ([**Fig. 5**](#pone-0100487-g005){ref-type="fig"} **,** [**6**](#pone-0100487-g006){ref-type="fig"}) suggested no evidence of publication bias in the meta-analysis of CYP1A2\*F (*P* = 0.160 for dominant model, *P* = 0.714 for recessive model, *P* = 0.862 for homozygote model; *P* = 0.248 for heterozygote model; *P* = 0.462 for additive model) and Leu432Val (*P* = 0.749 for dominant model, *P* = 0.864 for recessive model, *P* = 0.991 for homozygote model; *P* = 0.721 for heterozygote model; *P* = 0.689 for additive model), although possible publication bias was suggested for Asn453Ser polymorphism with colorectal cancer risk in additive model and recessive model and for Arg48Gly with colorectal cancer risk in any genetic model. This might be a limitation for meta-analysis of Arg48Gly and Asn453Ser polymorphisms, especially those with small sample size, are less likely to be published. [**Figure 7**](#pone-0100487-g007){ref-type="fig"} **,** [**8**](#pone-0100487-g008){ref-type="fig"} lists the Duval and Tweedie nonparametric "trim and fill" methods funnel plot in additive model and recessive model. Adjusting for possible publication bias using the Duval and Tweedie nonparametric "trim and fill" method for overall studies, the results did not change between Arg48Gly and Asn453Ser polymorphism with colorectal cancer risk.

![Begg\'s funnel plot of the meta-analysis of colorectal cancer risk and CYP1A2\*F polymorphism (homozygote model and dominant model).](pone.0100487.g005){#pone-0100487-g005}

![Begg\'s funnel plot of the meta-analysis of colorectal cancer risk and CYP1B1 Leu432Val polymorphism (homozygote model and dominant model).](pone.0100487.g006){#pone-0100487-g006}

![The Duval and Tweedie nonparametric "trim and fill" method\'s funnel plot funnel plot of the meta-analysis of colorectal cancer risk and CYP1B1 Arg48Gly polymorphism (additive model and dominant model).](pone.0100487.g007){#pone-0100487-g007}

![The Duval and Tweedie nonparametric "trim and fill" method\'s funnel plot funnel plot of the meta-analysis of colorectal cancer risk and CYP1B1 Asn453Ser polymorphism (additive model and dominant model).](pone.0100487.g008){#pone-0100487-g008}

Discussion {#s4}
==========

CYP1B1 is commonly over-expressed inhumanmalignancies and activates a variety of carcinogens. For example, CYP1B1 catalyzes both the formation of dihydrodiols of specific PAHs and their subsequent oxidation to carcinogenic dihydrodiol epoxides. The importance of CYP1B1 in chemical carcinogens is well illustrated in animal models in which metabolites of CYP1B1 were shown to induce Prostate cancer risk [@pone.0100487-Williams1], [@pone.0100487-Cavalieri1]. CYP 1A2 is an important gene in catalyzing 2- and 4-hydroxylations of estrogens and metabolism of carcinogens. A major reason for the limited number of studies of heterocyclic amine (HCA) and cancer risk is the difficulty of assessing human exposure to HCAs. HCA concentrations depend on cooking methods and the "doneness" level of the meat or fish, hampering the development of a complete and standardized database of concentrations; any estimation of dietary intake from food-frequency questionnaires (FFQs) is thus likely to result in misclassification. Like other environmental chemical carcinogens, HCAs require metabolic activation by host enzymes to become genotoxic. Phase I enzymes, including cytochrome P450 1A2, can metabolically activate carcinogens to form genotoxic electrophilic intermediates [@pone.0100487-McManus1]. The relative activity of these metabolizing enzymes, which is in large part genetically determined, is thought to be an important host determinant of cancer incidence. A number of epidemiological studies have evaluated the association between CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and colorectal cancer risk, but the results remain inconclusive. In order to resolve this conflict, this meta-analysis of 39 eligible studies including 5,817 cases and 6,544 controls for CYP1A2\*F (from 13 studies), 9,219 cases and 10,406 controls for CYP1B1 Leu432Val (from 12 studies), 6,840 cases and 7,761 controls for CYP1B1 Asn453Ser (from 8 studies), and 4,302 cases and 4,791 controls for CYP1B1 Arg48Gly (from 6 studies) was performed to derive a more precise estimation of the association between CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and risk of colorectal cancer.

Overall, no significant association was found between CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly when all the eligible studies were pooled into the meta-analysis. And in the subgroup, no evidence of significant association was also observed in any subgroup. Sachse et al. [@pone.0100487-Zhao1] in 2002 and Küry et al. [@pone.0100487-Kry1] in 2007 reported that CYP1B1 Leu432Val was not associated with increased the risk of colorectal cancer. Landi et al. [@pone.0100487-Landi1] and Huber et al. [@pone.0100487-Huber1] in 2005 reported that CYP1B1 Leu432Val and Asn453Ser polymorphisms were also not associated with increased the risk of colorectal cancer. Cleary et al. [@pone.0100487-Cleary1] in 2010 found that CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly were not associated with increased the risk of colorectal cancer. Sachse et al. [@pone.0100487-Sachse1] in 2002, Yoshida et al. [@pone.0100487-Yoshida1] in 2007, Kiss et al. [@pone.0100487-Kiss1] in 2007, and Cleary et al. [@pone.0100487-Cleary1] reported that CYP1A2\*F, was not associated with increased the risk of colorectal cancer. The results of our meta-analysis supported the negative association between CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and colorectal cancer risk. However, a careful matching should be considered in future larger genetic association studies including multiple ethnic groups.

We noticed that 3 previous meta-analysis [@pone.0100487-Zhao1], [@pone.0100487-Mei1], [@pone.0100487-Xie1] had been reported on the colorectal cancer risk with CYP1A2\*F, CYP1B1 Leu432Val, and Asn453Ser polymorphisms. We have read with great interest the meta-analysis by Mei et al. [@pone.0100487-Mei1] and Xie et al. [@pone.0100487-Xie1]. Mei et al. [@pone.0100487-Kry2] had 7 studies including 6,375 cases and 7,003 controls. The pooled analysis suggested that no significant association was found between the CYP1B1 Asn453Ser polymorphism and the risk of colorectal cancer among Caucasians. Xie et al. [@pone.0100487-Xie1] had 10 studies including 8,466 cases and 9,301 for Leu432Val. Their meta-analyses suggested that CYP1B1 Leu432Val were not associated with colorectal cancer risk. However, the study of Northwood et al. [@pone.0100487-Northwood1] should be excluded in the meta-analyses of Mei et al. [@pone.0100487-Mei1] and Xie et al. [@pone.0100487-Xie1] because they performed CYP1B1 Leu432Val with colorectal adenoma risk but not colorectal cancer. Adopting the same search strategy as Mei et al. [@pone.0100487-Mei1] and Xie et al. [@pone.0100487-Xie1], we identified 4 additional eligible studies, which have not been included in the meta-analysis of Xie et al. [@pone.0100487-Bethke1]. Worthy of note, these 4 studies included 3,638 samples. Zhao et al. [@pone.0100487-Zhao1] included 11 studies. Their meta-analysis suggests that the CYP1A2\*F polymorphism is a protective factor against CRC among Asians. The OR (95% CI) reported by Zhao et al. [@pone.0100487-Zhao1] for the study by Bae et al. [@pone.0100487-Bae1] do not seem in line with the OR (95% CI) provided by Bae et al. [@pone.0100487-Bae1] in their original publication. The OR (95% CI) reported by Zhao et al. [@pone.0100487-Zhao1] in additive model are 0.56 (0.38--0.84). Interestingly enough, after carefully studying the OR (95% CI) presented by Bae et al. [@pone.0100487-Bae1], The OR (95% CI) were 1.77 (1.18--2.66). In addition, the study of Wang et al. [@pone.0100487-Wang3] should be excluded in the meta-analysis of Zhao et al. [@pone.0100487-Zhao1] because the data on CYP1A2\*F polymorphism with colorectal cancer risk did not be found in the study of Wang et al. [@pone.0100487-Wang3]. Adopting the same search strategy as Zhao et al. [@pone.0100487-Zhao1], we identified 3 additional eligible studies, which have not been included in the meta-analysis of Zhao et al. [@pone.0100487-Zhao1]. Worthy of note, these 3 studies included 2687 samples. Having analyzed an almost twofold larger number of studies than the previous meta-analysis [@pone.0100487-Zhao1], [@pone.0100487-Mei1], [@pone.0100487-Xie1], our results seem to confirm and establish the trend in the meta-analysis of CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms that the data by the previous meta-analysis [@pone.0100487-Zhao1], [@pone.0100487-Mei1], [@pone.0100487-Xie1] had indicated. The results of the present meta-analysis are not in accordance with those reported by Zhao et al. [@pone.0100487-Zhao1]. Our meta-analysis indicates that CYP1A2\*F are not associated with colorectal cancer risk.

There are several limitations in this meta-analysis. First, the controls were not uniformly defined. Although most of them were common populations, some controls were population-based; other controls were hospital-based. Hence, non--differential misclassification bias is possible. Second, in the subgroup analysis may have had insufficient statistical power to check an association, Third, we were also unable to examine the interactions among gene-environment, lacking of the original data of the included studies limited our further evaluation of potential interactions, which may be an important component of the association between CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and environment and colorectal cancer risk. Last, our results were based on unadjusted published estimates. Because of data limitations, we were unable to adjust them such as age and alcohol consumption et al.

In summary, this meta-analysis indicates that CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly are not associated with colorectal cancer. However, it is necessary to conduct large sample studies using standardized unbiased genotyping methods, homogeneous cancer patients and well-matched controls. Moreover, further studies estimating the effect of gene--gene and gene--environment interactions may eventually lead to our better, comprehensive understanding of the association between the CYP1A2\*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and colorectal cancer risk.
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